Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin-Reference-Cited by-同舟云学术

Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin

Published:2019-07 Issue:7 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Dahesh Samira¹,Wong Brian²,Nizet Victor¹³^ORCID,Sakoulas George¹⁴,Tran Truc T.⁵⁶,Aitken Samuel L.⁵⁷

Affiliation:

1. University of California San Diego School of Medicine, La Jolla, California, USA

2. Division of Infectious Diseases, Loma Linda Jerry L. Pettis Memorial Veterans Medical Center, Loma Linda, California, USA

3. Skaggs School of Pharmacy, University of California San Diego, La Jolla, California, USA

4. Sharp Healthcare System, San Diego, California, USA

5. Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), UTHealth McGovern Medical School, Houston, Texas, USA

6. Department of Internal Medicine, Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, USA

7. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract

Weekly oritavancin plus ampicillin continuous infusion combination therapy was used to successfully treat a deep spine vancomycin-resistant Enterococcus faecium infection associated with hardware. Checkerboard and time-kill assays confirmed synergy between these two antibiotics.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02622-18

Reference16 articles.

1. Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010

2. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

3. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection